By FieldPulse Staff · March 17, 2026
Tags: launch, strategy
Vertex Phase 3 RAINIER trial shows 52% proteinuria reduction with povetacicept in IgAN. BLA submission by end of March 2026; potential approval November 2026.
Vertex Pharmaceuticals announced positive results from its Phase 3 RAINIER trial in IgA nephropathy (IgAN) on March 17, 2026. Its drug povetacicept — a dual inhibitor of BAFF and APRIL cytokines — achieved its primary endpoint, showing a 52% reduction from baseline in urine protein-to-creatinine ratio and a 49.8% placebo-adjusted reduction (p<0.0001). The drug also resolved hematuria (blood in urine, a key disease marker) in 85% of treated patients. Vertex said it plans to complete its rolling BLA submission to the FDA by end of March 2026, with analysts estimating a potential approval as earl